Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Publication year range
1.
Fortschr Neurol Psychiatr ; 81(1): 21-7, 2013 Jan.
Article in German | MEDLINE | ID: mdl-22890440

ABSTRACT

Non-convulsive status epilepticus and epilepsia partialis continua are common epileptic conditions for which straightforward recommendations based on controlled randomised trials for treatment of therapy refractory courses are lacking. Therefore in these conditions sometimes antiepileptic drugs that are not approved by governmental authorities for the treatment of status epilepticus (SE) are used. Here we review all case reports and case series concerning the treatment of SE with levetiracetam (LEV), that had been listed in pub-med up to December 12th 2011. Additionally we analysed abstracts and papers in peer reviewed journals, that were listed in the references of the primarily reviewed papers. Furthermore we looked for LEV treatments in papers on the use of lacosamide (LCM) in SE. LEV was given in dosages ranging from 500 mg to 9000 mg per day. Side effects were especially sedation and irritability. Estimated on the basis of the case series the overall success-rate of LEV in terminating status epilepticus may be set in a range between 53.7% and 58.1%. Therefore LEV may be a useful alternative for the treatment of SE when the approved drugs are contraindicated or when these drugs have been taken without success.


Subject(s)
Anticonvulsants/therapeutic use , Piracetam/analogs & derivatives , Status Epilepticus/drug therapy , Anticonvulsants/administration & dosage , Anticonvulsants/adverse effects , Epilepsia Partialis Continua/drug therapy , Humans , Levetiracetam , Piracetam/administration & dosage , Piracetam/adverse effects , Piracetam/therapeutic use
2.
J Neural Transm (Vienna) ; 120(3): 453-61, 2013 Mar.
Article in English | MEDLINE | ID: mdl-22892823

ABSTRACT

Progressive supranuclear palsy (PSP) is the most common atypical parkinsonian syndrome and an important differential diagnosis of parkinson's disease (PD). The clinical diagnosis of PSP relies on characteristic symptoms. There is evidence of clinical subgroups within the entity of PSP interfering with making the firm diagnosis. It was the aim of the study to clarify the differences between phenotypical subtypes of PSP and PD focusing on transcallosal inhibition (TI). A systematic chart review of 67 patients supposed to have probable PSP was done in a standardized diagnostic work-up. As only complete data sets were included into further analysis, 26 PSP patients (mean age 68.6 ± 7.1 years) could be evaluated and subdivided into Richardson's syndrome (RS) (n = 15) or PSP of parkinsonian type (PSP-P) (n = 11). Fifteen PD patients served as controls. TI was evaluated by investigation of the ipsilateral silent period (iSP) with transcranial magnetic stimulation (TMS). Cognition was assessed by the Addenbrooke's cognitive examination (ACE-R). TMS revealed a significantly more severe affection of TI in RS patients as compared to PSP-P and PD patients who showed similar neurophysiological findings. 47 % of RS patient displayed an iSP loss, whereas PSP-P and PD did not. There was a significant correlation between iSP latency and ACE-R (Spearman's coefficient -0.369, P = 0.010). In conclusion, RS patients-contrary to PSP-P and PD patients-had pathological TI at least in one hemisphere indicating more severe involvement of transcallosally projecting output neurons in RS.


Subject(s)
Functional Laterality/physiology , Neural Inhibition/physiology , Parkinson Disease/diagnosis , Supranuclear Palsy, Progressive/diagnosis , Aged , Female , Humans , Male , Parkinson Disease/physiopathology , Phenotype , Supranuclear Palsy, Progressive/physiopathology , Transcranial Magnetic Stimulation
SELECTION OF CITATIONS
SEARCH DETAIL
...